CASTLE BIOSCIENCES INC (CSTL): Price and Financial Metrics


-0.49 (-2.44%)

POWR Rating

Component Grades














  • CSTL scores best on the Quality dimension, with a Quality rank ahead of 48.62% of US stocks.
  • CSTL's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • CSTL's current lowest rank is in the Growth metric (where it is better than 3.54% of US stocks).

CSTL Stock Summary

  • Castle Biosciences Inc's stock had its IPO on July 25, 2019, making it an older stock than merely 7.54% of US equities in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.07 for Castle Biosciences Inc; that's greater than it is for only 6.92% of US stocks.
  • Over the past twelve months, CSTL has reported earnings growth of 428.83%, putting it ahead of 94.9% of US stocks in our set.
  • Stocks that are quantitatively similar to CSTL, based on their financial statements, market capitalization, and price volatility, are SMAR, PRCH, FTK, PING, and MARK.
  • CSTL's SEC filings can be seen here. And to visit Castle Biosciences Inc's official web site, go to

CSTL Valuation Summary

  • CSTL's price/sales ratio is 24.7; this is 550% higher than that of the median Healthcare stock.
  • Over the past 26 months, CSTL's price/sales ratio has gone up 10.2.
  • CSTL's price/sales ratio has moved up 10.2 over the prior 26 months.

Below are key valuation metrics over time for CSTL.

Stock Date P/S P/B P/E EV/EBIT
CSTL 2021-08-31 24.7 4.6 -85.6 -73.2
CSTL 2021-08-30 24.0 4.5 -83.2 -70.6
CSTL 2021-08-27 23.9 4.5 -82.9 -70.3
CSTL 2021-08-26 23.4 4.4 -81.0 -68.2
CSTL 2021-08-25 23.4 4.4 -81.1 -68.3
CSTL 2021-08-24 23.6 4.4 -81.9 -69.2

CSTL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CSTL has a Quality Grade of D, ranking ahead of 17.49% of graded US stocks.
  • CSTL's asset turnover comes in at 0.205 -- ranking 69th of 81 Healthcare stocks.
  • 500 - Internal server error

The table below shows CSTL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.205 0.848 -1.507
2021-03-31 0.211 0.848 -0.890
2020-12-31 0.258 0.845 -0.387
2020-09-30 0.386 0.857 -0.011
2020-06-30 0.451 0.868 0.367
2020-03-31 0.627 0.866 0.356

CSTL Price Target

For more insight on analysts targets of CSTL, see our CSTL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $88.50 Average Broker Recommendation 1.17 (Strong Buy)

CSTL Stock Price Chart Interactive Chart >

Price chart for CSTL

CSTL Price/Volume Stats

Current price $19.62 52-week high $78.92
Prev. close $20.11 52-week low $17.01
Day low $19.24 Volume 202,663
Day high $20.64 Avg. volume 303,753
50-day MA $29.62 Dividend yield N/A
200-day MA $47.13 Market Cap 515.24M


Castle Biosciences, Inc. provides healthcare imaging services. The Company offers diagnostic and prognostic testing solutions for cancers, as well as research and development activities. Castle Biosciences serves customers in the United States.

CSTL Latest News Stream

Event/Time News Detail
Loading, please wait...

CSTL Latest Social Stream

Loading social stream, please wait...

View Full CSTL Social Stream

Latest CSTL News From Around the Web

Below are the latest news stories about Castle Biosciences Inc that investors may wish to consider to help them evaluate CSTL as an investment opportunity.

Castle Biosciences Q4 2021 Earnings Preview

Castle Biosciences (NASDAQ:CSTL) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close. The consensus EPS Estimate is -$0.48 (-108.7% Y/Y) and the consensus Revenue Estimate is $24.15M (+39.6% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue...

Seeking Alpha | February 25, 2022

Castle Biosciences Q4 2021 Earnings Preview (NASDAQ:CSTL)

Castle Biosciences (NASDAQ:CSTL) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.48 (-108.7% Y/Y) and…

Seeking Alpha | February 25, 2022

The Joint Corp. (JYNT) Q4 Earnings Lag Estimates

The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Earnings Preview: Castle Biosciences, Inc. (CSTL) Q4 Earnings Expected to Decline

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022

FRIENDSWOOD, Texas, February 14, 2022--Castle will release its financial results for the fourth quarter and year-ended Dec. 31, 2021, after the close of market on Monday, Feb. 28, 2022.

Yahoo | February 14, 2022

Read More 'CSTL' Stories Here

CSTL Price Returns

1-mo -17.63%
3-mo -54.70%
6-mo -54.50%
1-year -67.77%
3-year N/A
5-year N/A
YTD -54.23%
2021 -36.16%
2020 95.37%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6959 seconds.